Navigation Links
Dyadic International To Present At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech
Date:5/29/2013

JUPITER, Fla., May 29, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), announced today that its President and CEO, Mark Emalfarb , will present at the World Biotechnology Congress 2013 in Boston, Massachusetts and the BIO World Congress on Industrial Biotech in Montreal, Canada.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic is a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Emalfarb's presentation at the World Biotechnology Congress will take place on June 6th, from 11:20 – 11:40 a.m. EDT, in Lecture Hall No. 201 (Level 2) at the John B. Hynes Veterans Memorial Convention Center.

Titled "Dyadic's C1 Enzyme Technology Update: On the Road to Cellulosic Sugars for Fuels and Chemicals," Emalfarb will discuss Dyadic's license agreements, commercial developments and progress toward producing cost-competitive cellulosic biofuels from agricultural byproducts such as corn stover and wheat straw.

Emalfarb will also co-chair the Industrial and Manufacturing session scheduled for Thursday, June 6th, from 2:00 – 5:10 p.m. EDT in Lecture Hall No. 201.  The session will feature presentations on next-generation biofuels and new routes toward the development of novel antifungal therapeutics, among others.

At the BIO World Congress on Industrial Biotech on June 18th, Emalfarb will participate on a panel called "Global Benefits for Synthetic Biology Tools" from 10:30 a.m. – 12:00 p.m. EDT at the Palais des Congres de Montreal.

"Dyadic is making significant progress towards producing economically viable cellulosic biofuels and chemicals from C1-derived enzymes," said Emalfarb.  "For instance, we expect that our C1 platform will be used to produce enzymes in commercial volumes when Abengoa Energy starts up its commercial scale cellulosic ethanol biorefinery in Hugoton, Kansas later this year."

Emalfarb continued, "We look forward to providing an update on this and other commercial developments at both of these internationally recognized scientific conferences."

About World Biotechnology Congress 2013

The World Biotechnology Congress 2013 will focus on various important disciplines of biotechnology and its applications for improvement in health and quality of life the world over.  It is anticipated that up to 1000 of the world's leading scientists, researchers, industrialists and academicians, including several Nobel Laureates, in the fields of biotechnology as well as medical and biological sciences, will attend this forum in Boston, to share and discuss new scientific ideas, products and breakthroughs.

About BIO World Congress

The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event for business leaders, investors, and policy makers in biofuels, bio-based products, and renewable chemicals.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Reports First Quarter 2013 Financial Results
2. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
3. Danai Brooks Joins Dyadic International as Chief Operating Officer
4. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
5. Dyadic International To Present At World Biofuels Markets
6. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
7. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
8. 12th U.S. Patent Issued To Dyadic International
9. Dyadic International Reports 2012 Third Quarter Financial Results
10. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
11. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):